Potential of dendritic cell immunotherapy for relapse after allogeneic hematopoietic stem cell transplantation, shown by WT1 peptide- and keyhole limpet hemocyanin-pulsed, donor-derived dendritic cell vaccine for acute myeloid leukemia

American Journal of Hematology

Volumn 83, Issue 4, 2008, Pages 315-317

  Kitawaki, Toshio ^a   Kadowaki, Norimitsu ^a,b   Kondo, Tadakazu ^a   Ishikawa, Takayuki ^a   Ichinohe, Tatsuo ^a   Teramukai, Satoshi ^a   Fukushima, Masanori ^a   Kasai, Yasunari ^a   Maekawa, Taira ^a   Uchiyama, Takashi ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYTARABINE; DAUNORUBICIN; DENDRITIC CELL VACCINE; FLUDARABINE; KEYHOLE LIMPET HEMOCYANIN; METHOTREXATE; TACROLIMUS; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANTIGEN SPECIFICITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; DISEASE COURSE; DONOR; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; PRIORITY JOURNAL; RADIATION DOSE; RELAPSE;

ADJUVANTS, IMMUNOLOGIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; COMBINED MODALITY THERAPY; CYTARABINE; DAUNORUBICIN; DENDRITIC CELLS; DISEASE PROGRESSION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOCYANIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY, ACTIVE; LEUKEMIA, MYELOMONOCYTIC, ACUTE; LIVING DONORS; MIDDLE AGED; PEPTIDE FRAGMENTS; PHOSPHOPROTEINS; SALVAGE THERAPY; SIBLINGS; TRANSPLANTATION, HOMOLOGOUS; VIRAL MATRIX PROTEINS; WT1 PROTEINS;

EID: 41449110340     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21127     Document Type: Article

References (19)

1. Scheibenbogen C, Letsch A, Thiel E, et al. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 2002;100:2132-2137.
2. Rezvani K, Grube M, Brenchley JM, et al. Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood 2003;102:2892-2900.
3. Oka Y, Tsuboi A, Taguchi T, et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 2004;101:13885-13890.
4. Rezvani K, Brenchley JM, Price DA, et al. T-Cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: Identification, quantification, and characterization. Clin Cancer Res 2005;11:8799-8807.
5. Morita Y, Heike Y, Kawakami M, et al. Monitoring of WT1-specific cytotoxic T lymphocytes after allogeneic hematopoietic stem cell transplantation. Int J Cancer 2006;119:1360-1367.
6. Mailander V, Scheibenbogen C, Thiel E, et al. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia 2004;18:165-166.
7. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005;5:296-306.
8. Tatsugami K, Eto M, Harano M, et al. Dendritic-cell therapy after non-myeloablative stem-cell transplantation for renal-cell carcinoma. Lancet Oncol 2004;5:750-752.
9. Tsuboi A, Oka Y, Udaka K, et al. Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues. Cancer Immunol Immunother 2002;51:614-620.
10. Kuzushima K, Hayashi N, Kimura H, et al. Efficient identification of HLA-A*2402-restricted cytomegalovirus-specific CD8+ T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay. Blood 2001;98:1872-1881.
11. Ljungman P, Engelhard D, de la Camara R, et al. Vaccination of stem cell transplant recipients: Recommendations of the Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant 2005;35:737-746.
12. Anderson LD Jr, Savary CA, Mullen CA. Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus-tumor activity without exacerbating graft-versus-host disease. Blood 2000;95:2426-2433.
13. Teshima T, Mach N, Hill GR, et al. Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation. Cancer Res 2001;61:162-171.
14. Moyer JS, Maine G, Mule JJ. Early vaccination with tumor lysate-pulsed dendritic cells after allogeneic bone marrow transplantation has antitumor effects. Biol Blood Marrow Transplant 2006;12:1010-1019.
15. Fujii S, Shimizu K, Fujimoto K, et al. Treatment of post-transplanted, relapsed patients with hematological malignancies by infusion of HLA-matched, allogeneic-dendritic cells (DCs) pulsed with irradiated tumor cells and primed T cells. Leuk Lymphoma 2001;42:357-369.
16. Dhodapkar MV, Steinman RM, Sapp M, et al. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest 1999;104:173-180.
17. Banchereau J, Palucka AK, Dhodapkar M, et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 2001;61:6451-6458.
18. de Vries IJM, Bernsen MR, Lesterhuis WJ, et al. Immunomonitoring Tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol 2005;23:5779-5787.
19. Thomas-Kaskel A-K, Zeiser R, Jochim R, et al. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival. Int J Cancer 2006;119:2428-2434.